US FDA VISITED YASHODA SUPERFICIALITY HOSPITAL TO ASSESS ADVERSE DRUGS REACTION MONITORING CENTER PERFORMANCE
A Team of
experts from The United states Food & Drug Administration (FDA), Central
Drugs Standard Control organisation pharmacopoeia Commission today visited The Yashoda
Supers specialty Hospital which is a registered adverse drugs reaction monitoring
center of Pharmacovigilance programmer of India (PVPI).
Experts
inquired about practices adopted there to monitor adverse drugs reactions and programme's efficacy.the team
was taken on hospital round to show them the practices in the hospital’s
clinical areas.
On seeing the
process and infrastructure, Dr Gerald Dal Pan- Director office of surveillance and
epidemiology US-FDA appreciated the work,and observed that facilities there were as as good as in US. He
commented that in US maximum, adverse drug reaction cases come from outpatient
wing but In India, it is different as maximum cases cases come here from in
patient sections.
Dr Ademola of
FDA did talk to nurses to understand their awareness on the ongoing programme and lacunae id any.
Delgates
among others included Dr Sudheendra Kulkarni, Meducak product Safety Coordinator
, FDA,Ms. Rubina Bose , Mr Vipin of PvPI.
Dr Rahul Shukla , A director of the Hospital . gave brief presentation while children Dr Sunil Dagar Dgar, GM(operations) took the delegation to the round.
Comments
Post a Comment